PMID- 32949656
OWN - NLM
STAT- MEDLINE
DCOM- 20210125
LR  - 20221207
IS  - 1872-8227 (Electronic)
IS  - 0168-8227 (Linking)
VI  - 169
DP  - 2020 Nov
TI  - Age- and sex-specific incidence of non-traumatic lower limb amputation in 
      patients with type 2 diabetes mellitus in a U.S. claims database.
PG  - 108452
LID - S0168-8227(20)30705-1 [pii]
LID - 10.1016/j.diabres.2020.108452 [doi]
AB  - AIM: To estimate age- and sex-specific incidence rates (IRs) of non-traumatic 
      lower limb amputations (LLA) in patients with type 2 diabetes mellitus (T2DM) 
      using a claims database from the United States (US). METHODS: Patients with T2DM 
      18 years and older were identified using the Truven Health MarketScan database 
      from January 1, 2007 to September 30, 2018. The overall and age- and sex-specific 
      IRs of all non-traumatic LLA, minor LLA (amputation at or below the ankle), and 
      major LLA (amputation above ankle) were calculated. RESULTS: Among the 6,117,981 
      patients with T2DM, 14,627 LLA events occurred (minor LLA; 72.8%; major LLA: 
      27.2%). The IRs (95% CI) of all LLA, minor LLA, and major LLA per 1000 
      person-years or PY were 0.86 (0.85, 0.88), 0.63 (0.62, 0.64), and 0.23 (0.23, 
      0.24), respectively. The IR (95% CI) of all LLA per 1000 PY in males was higher 
      compared to females [1.24 (1.22, 1.26) vs. 0.46 (0.45, 0.48)]. The incidence of 
      all LLA increased with an increasing age (highest IR in age-group of >/=80 years). 
      CONCLUSIONS: This study identified males and older patients with T2DM at higher 
      risk of developing LLA in the US, warranting further exploration of risk factors 
      of LLA in these subgroups.
CI  - Copyright (c) 2020 Elsevier B.V. All rights reserved.
FAU - Gandhi, Sampada K
AU  - Gandhi SK
AD  - Epidemiology and Benefit Risk, Sanofi U.S., 55 Corporate Drive, Bridgewater, NJ 
      08807, USA. Electronic address: sampada.gandhi@sanofi.com.
FAU - Waschbusch, Max
AU  - Waschbusch M
AD  - Global Pharmacovigilance, Sanofi U.S., 55 Corporate Drive, Bridgewater, NJ 08807, 
      USA.
FAU - Michael, Madlen
AU  - Michael M
AD  - Global Pharmacovigilance, Sanofi U.S., 55 Corporate Drive, Bridgewater, NJ 08807, 
      USA.
FAU - Zhang, Meng
AU  - Zhang M
AD  - Global Pharmacovigilance, Sanofi U.S., 55 Corporate Drive, Bridgewater, NJ 08807, 
      USA.
FAU - Li, Xinyu
AU  - Li X
AD  - Epidemiology and Benefit Risk, Sanofi U.S., 55 Corporate Drive, Bridgewater, NJ 
      08807, USA.
FAU - Juhaeri, Juhaeri
AU  - Juhaeri J
AD  - Epidemiology and Benefit Risk, Sanofi U.S., 55 Corporate Drive, Bridgewater, NJ 
      08807, USA.
FAU - Wu, Chuntao
AU  - Wu C
AD  - Epidemiology and Benefit Risk, Sanofi U.S., 55 Corporate Drive, Bridgewater, NJ 
      08807, USA.
LA  - eng
PT  - Journal Article
DEP - 20200917
PL  - Ireland
TA  - Diabetes Res Clin Pract
JT  - Diabetes research and clinical practice
JID - 8508335
SB  - IM
MH  - Age Factors
MH  - Aged
MH  - Amputation, Surgical/*methods
MH  - Databases, Factual
MH  - Diabetes Mellitus, Type 2/*complications/epidemiology
MH  - Female
MH  - Humans
MH  - Incidence
MH  - Lower Extremity/*surgery
MH  - Male
MH  - Middle Aged
MH  - Risk Factors
MH  - Sex Factors
MH  - United States
OTO - NOTNLM
OT  - Incidence rate
OT  - Lower limb amputation
OT  - Type 2 diabetes mellitus
COIS- Declaration of Competing Interest The authors declare that they have no known 
      competing financial interests or personal relationships that could have appeared 
      to influence the work reported in this paper.
EDAT- 2020/09/20 06:00
MHDA- 2021/01/26 06:00
CRDT- 2020/09/19 20:09
PHST- 2020/05/04 00:00 [received]
PHST- 2020/07/22 00:00 [revised]
PHST- 2020/09/14 00:00 [accepted]
PHST- 2020/09/20 06:00 [pubmed]
PHST- 2021/01/26 06:00 [medline]
PHST- 2020/09/19 20:09 [entrez]
AID - S0168-8227(20)30705-1 [pii]
AID - 10.1016/j.diabres.2020.108452 [doi]
PST - ppublish
SO  - Diabetes Res Clin Pract. 2020 Nov;169:108452. doi: 10.1016/j.diabres.2020.108452. 
      Epub 2020 Sep 17.